A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA
Cogent Biosciences (COGT) is under investor scrutiny following the FDA's acceptance of its New Drug Application for bezuclastinib in Gastrointestinal Stromal Tumors. Despite a recent share price decline, the company shows strong long-term shareholder returns. The article analyzes Cogent's valuation, noting its high Price-to-Book ratio compared to the industry average but a discount when measured against direct peers, suggesting a balanced risk-reward profile tied to future clinical outcomes.
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA
Cogent Biosciences is under investor scrutiny after the FDA accepted its New Drug Application for bezuclastinib, a drug reducing disease progression risk by 50% in Gastrointestinal Stromal Tumors. Valued at $5.7 billion with a P/B ratio of 10.4x, it's considered expensive compared to the broader biotech industry but discounted relative to its direct peers, despite significant net losses and minimal revenue. The company faces high risks due to its early stage, reliance on trial outcomes, and FDA decisions.
[Form 4] Cogent Biosciences, Inc. Insider Trading Activity
Cogent Biosciences director Karen Jean Ferrante received a stock option award for 686 shares, granted on April 1, 2026, with an exercise price of $35.24 and an expiration date of April 1, 2036. This award was compensation for her services as a non-employee director, where she opted for stock options instead of cash. Following this transaction, she directly holds options for 686 shares.
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
Guggenheim has reiterated its Buy rating on Cogent Biosciences (COGT.US) and maintained a target price of $45. This suggests a continued positive outlook on the company's stock performance by the investment firm.
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT)
Cogent Biosciences (COGT) maintains a Buy rating due to the perceived blockbuster potential of bezuclastinib in treating GIST and systemic mastocytosis, with the PEAK trial showing strong efficacy in GIST. Despite a premium valuation and competitive/regulatory risks, the company's differentiated profile and potential for M&A activity support a bullish outlook. The sum-of-the-parts valuation suggests a fair value of $26.54/share, with current cash reserves likely sufficient until commercial launch, though dilution remains a risk.
Cogent files new GIST drug after trial cut progression risk 50%
Cogent Biosciences (COGT) has submitted a New Drug Application (NDA) to the FDA for bezuclastinib in imatinib-resistant Gastrointestinal Stromal Tumors (GIST). This submission follows positive Phase 3 PEAK trial data showing a 50% reduction in disease progression risk and improved objective response rates. The NDA was filed under the FDA’s Real-Time Oncology Review (RTOR) program, indicating a potentially expedited review process, though the stock reacted negatively on the news, possibly due to profit-taking or valuation concerns.
Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GIST - Has The Bull Case Changed?
Cogent Biosciences submitted a New Drug Application to the FDA for bezuclastinib in previously treated GIST, following positive Phase 3 PEAK trial results and Breakthrough Therapy Designation. The company aims for bezuclastinib to become a commercial franchise for systemic mastocytosis and GIST, but faces near-term risks including regulatory setbacks, reimbursement hurdles, and potential shareholder dilution. Investors are encouraged to consider various perspectives and the company's financial health before making investment decisions.
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors
Cogent Biosciences has submitted a New Drug Application (NDA) for bezuclastinib to the FDA for patients with Gastrointestinal Stromal Tumors (GIST) who have previously been treated with imatinib. This submission is based on positive Phase 3 PEAK trial results, demonstrating significant improvement in progression-free survival and overall response rate for imatinib-resistant patients. The NDA was submitted under the FDA's Real-Time Oncology Review program, and bezuclastinib also holds Breakthrough Therapy Designation for GIST.
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2% - Should You Sell?
Cogent Biosciences (NASDAQ:COGT) stock fell 10.2% on Wednesday, with trading volume 45% lower than the average session. Analysts have mixed views, with a consensus "Moderate Buy" rating and a $43.45 price target, despite the company missing EPS estimates and a significant insider sale of 3.5 million shares by Fairmount Funds Management LLC. The company is a clinical-stage biopharmaceutical firm focused on developing small-molecule therapies for the tumor microenvironment.
Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GIST - Has The Bull Case Changed?
Cogent Biosciences (COGT) has filed an NDA with the FDA for bezuclastinib for GIST, boosted by positive Phase 3 trial results and Breakthrough Therapy Designation. This filing, coupled with other regulatory submissions, intensifies the focus on upcoming FDA decisions and is a significant new catalyst for the company. However, the company faces risks including near-term clinical setbacks, potential dilution due to funding needs, and an estimated inflated share price compared to its fair value.
Cogent Biosciences Announces Submission of New Drug
Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat Gastrointestinal Stromal Tumors (GIST) in patients previously treated with imatinib. The submission, based on positive Phase 3 PEAK trial results, was filed under the FDA’s Real-Time Oncology Review program, following bezuclastinib's Breakthrough Therapy Designation. The company also announced inducement grants to new employees and outlined future trial plans.
Cogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib
Cogent Biosciences (COGT) stock fell about 6% after submitting a New Drug Application (NDA) for bezuclastinib to the U.S. FDA for Gastrointestinal Stromal Tumors. The NDA was filed under the FDA's Real-Time Oncology Review program, supported by positive findings from the PEAK trial. The stock is currently trading at $35.86, down 6.86% from its previous close.
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat gastrointestinal stromal tumors (GIST) in patients previously treated with imatinib. The submission is based on positive results from the Phase 3 PEAK trial, showing significant benefits in progression-free survival and objective response rates, and was submitted under the FDA’s Real-Time Oncology Review program. Bezuclastinib previously received Breakthrough Therapy Designation for GIST.
Fairmount Funds trims Cogent Biosciences (COGT) position after 7M-share block sale
Fairmount Funds Management LLC and its affiliates have reported an updated ownership in Cogent Biosciences (COGT) after converting preferred stock and selling a substantial block of shares. The entities now beneficially own 15,356,918 shares of common stock, which represents 8.6% of the company. This change includes the conversion of 28,000 Series A Preferred Stock shares into 7,000,000 common shares and the subsequent sale of these 7,000,000 common shares in a block trade for $34.66 per share on March 31, 2026.
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
UBS analysts have identified several top healthcare stock picks, emphasizing companies with underappreciated earnings durability and significant upcoming catalysts. Cogent Biosciences (NASDAQ:COGT) is highlighted in biotech for its late-stage assets and blockbuster potential, while Cigna Group (NYSE:CI) is favored in managed care due to a valuation disconnect and expected earnings growth. Other picks include CVS Health Corp, Merck & Co Inc, United Therapeutics Corporation, and CG Oncology, all chosen for strategic reasons like recovery stories, pipeline strength, or asymmetric upside potential.
Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT
Hennion & Walsh Asset Management Inc. increased its stake in Cogent Biosciences (NASDAQ:COGT) by 12.6% in the fourth quarter, acquiring an additional 37,938 shares to reach a total of 338,065 shares valued at approximately $12 million. Other institutional investors like Deerfield Management and Commodore Capital also significantly boosted their holdings. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and an average price target of $43.45.
Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation
Stifel has initiated coverage of Cogent Biosciences (COGT) with a Hold recommendation. The financial firm did not provide specific price targets, but this initiation suggests an early analytical assessment of the company's prospects.
Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT
Assenagon Asset Management S.A. significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 34.9% in Q4, selling over 200,000 shares. This move follows a major insider sale where Director Fairmount Funds Management Llc sold 3.5 million shares, decreasing their ownership by nearly 39%. Despite these sales, analysts maintain a "Moderate Buy" rating for COGT with an average price target of $43.45.
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
Cogent Biosciences has initiated a first-in-human Phase 1 clinical trial for CGT6297, a mutant-selective inhibitor targeting PIK3CA-driven cancers. This open-label study will assess the safety and anti-tumor activity of the daily oral drug in patients with advanced solid tumors harboring PIK3CA mutations, which are common in various cancers like endometrial and certain breast cancers. While still in the planning stage, this trial represents a potential future catalyst for COGT stock, adding an important asset to their drug pipeline.
Vanguard disaggregates holdings; Cogent Biosciences (COGT) shows 0% ownership
The Vanguard Group filed an amended Schedule 13G reporting 0% beneficial ownership of Cogent Biosciences common stock. This is due to an internal realignment effective January 12, 2026, where Vanguard disaggregated certain subsidiary holdings, meaning Vanguard no longer beneficially owns those positions. The filing clarifies that this is an administrative update and does not change Cogent's outstanding shares or control structure.
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest
Cogent Biosciences (COGT) has received FDA acceptance for its New Drug Application for bezuclastinib, leading to renewed investor interest despite the company currently reporting losses. The stock trades at a 10.4x Price to Book ratio, similar to peers but significantly higher than the broader biotech industry average, indicating investors are valuing its future pipeline. The article suggests reviewing key data and warning signs to assess whether the current valuation still offers a buying opportunity.
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest
Cogent Biosciences (COGT) is under scrutiny following FDA acceptance of its New Drug Application for bezuclastinib, leading to a volatile stock performance. Despite strong stock growth over the past year and a significant discount to analyst price targets, the company still faces risks including ongoing large losses and no current meaningful revenue, making its high price-to-book ratio a point of contention. The article suggests investors review underlying data and consider the key risks and rewards before making investment decisions.
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions
Cogent Biosciences (COGT) recently saw its share price increase by 6.08% following the FDA's acceptance of its New Drug Application for bezuclastinib, with a PDUFA target action date of December 30, 2026. The stock trades at a P/B ratio of 10.4x, slightly below its direct peer group but significantly above the broader US biotech industry, indicating a valuation heavily influenced by future growth expectations. Investors are encouraged to assess the details and risks, including potential clinical data disappointments, to decide if a buying opportunity remains.
Trading the Move, Not the Narrative: (COGT) Edition
This article provides an AI-generated analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss zones. The analysis also emphasizes the exceptional 72.5:1 risk-reward setup, targeting a substantial gain with minimal risk.
RTW Investments Increases Cogent Biosciences Stake to 2.7% of Portfolio - News and Statistics
RTW Investments, LP significantly increased its stake in Cogent Biosciences during Q1 2026, acquiring 4,124,755 shares valued at an estimated $115.95 million. This transaction raised Cogent Biosciences to 2.7% of RTW Investments' reportable assets under management, reflecting strong conviction in the biotechnology firm's precision therapies and its lead drug candidate, which is progressing towards potential commercialization. The strategic investment aligns with Cogent Biosciences' extended financial runway and upcoming regulatory decision for its lead candidate.
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
The FDA has accepted Cogent Biosciences' New Drug Application for bezuclastinib in non-advanced systemic mastocytosis, granting it Priority Review. This decision leads to a PDUFA date in December and comes after promising results from the SUMMIT clinical trial, potentially offering a new treatment option for patients.
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio Update - News and Statistics
Kynam Capital Management significantly reduced its stake in Cogent Biosciences in Q4 2025, selling 1,720,949 shares valued at $48.38 million. Despite this sale, Cogent Biosciences remains Kynam Capital's top position, comprising 14.3% of its reported assets under management. The article also touches upon Cogent Biosciences' market capitalization, net loss, cash position, and a key drug candidate awaiting regulatory review.
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
LifeSci Capital has reiterated its Buy rating for Cogent Biosciences (COGT.US) and maintained its target price at $55. This continued positive outlook suggests the firm sees strong potential in the company's future performance.
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026
Boone Capital Management fully divested its position in Cogent Biosciences (NASDAQ:COGT) after the stock surged 372% over the past year. The firm reallocated capital, and its newer investment in TYRA has already seen a 40% rise this year. Cogent Biosciences, despite its strong financial position and promising pipeline, may have much of its short-term upside already priced in.
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat NonAdvanced Systemic Mastocytosis (NonAdvSM), setting a PDUFA target action date of December 30, 2026. The FDA currently has no plans for an advisory committee meeting and has not identified potential review issues. The NDA is based on positive clinical results from the SUMMIT pivotal trial, which demonstrated significant improvements in symptoms and a favorable safety profile for bezuclastinib.
HC Wainwright Analysts Lift Earnings Estimates for COGT
HC Wainwright analysts have increased their Q1 2026 EPS estimate for Cogent Biosciences (COGT) to ($0.53) from ($0.54), maintaining a "Buy" rating and a $52 price target. The firm also projects FY2026 EPS of ($2.21), an improvement over the consensus estimate of ($2.42). Despite positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $43.45, company insiders have recently sold a significant number of shares.
How FDA Acceptance of Bezuclastinib NDA and SUMMIT Data Will Impact Cogent Biosciences (COGT) Investors
The article discusses the FDA's acceptance of Cogent Biosciences' New Drug Application for bezuclastinib, highlighting its strong clinical trial data for Non-Advanced Systemic Mastocytosis. It analyzes the investment implications for COGT, noting the company's high cash burn and the challenges of execution post-approval, despite the promising drug data. The piece also suggests that COGT's current share price might be inflated according to some valuations.
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND)
Two analysts have offered bullish sentiments on healthcare companies Cogent Biosciences (COGT) and Ascendis Pharma (ASND). H.C. Wainwright reiterated a Buy rating for Cogent Biosciences with a $52 price target, while Wedbush maintained a Buy rating on Ascendis Pharma with a $273 price target. Both companies also received initial Buy ratings from Jefferies, indicating strong analyst confidence.
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM
Cogent Biosciences' (COGT) stock rose after the FDA accepted its New Drug Application (NDA) for bezuclastinib to treat non-advanced systemic mastocytosis (NonAdvSM). The FDA is expected to make a decision by December 30, 2026, with the NDA supported by positive results from the SUMMIT clinical trial. Cogent is also developing bezuclastinib for advanced SM and gastrointestinal stromal tumors (GIST).
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences (COGT) saw its stock rise after the FDA accepted its New Drug Application (NDA) for bezuclastinib to treat non-advanced systemic mastocytosis (NonAdvSM). The FDA is expected to make a decision by December 30, 2026, with no advisory committee currently planned and no review concerns identified. The NDA is supported by positive data from the pivotal SUMMIT study, which showed significant and sustained improvements in symptoms and a favorable safety profile for bezuclastinib.
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT
Cinctive Capital Management LP has disclosed the purchase of 111,058 shares of Cogent Biosciences, Inc. (NASDAQ:COGT) during the third quarter, valued at approximately $1,595,000. This new position makes Cinctive Capital Management LP the owner of 0.08% of Cogent Biosciences. Other institutional investors have also adjusted their holdings, with several analysts offering various ratings and price targets for COGT shares.
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT
Boothbay Fund Management LLC significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 67.8% in the third quarter of 2025, selling over 400,000 shares. Despite this and considerable insider selling totaling $136.6 million, Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $43.45 for the stock, which currently trades around $35.68. The article also details other institutional investor activity and Cogent Biosciences' financial performance.
Cogent Biosciences (COGT) Valuation In Focus After FDA Accepts Bezuclastinib NDA For Systemic Mastocytosis
The FDA has accepted Cogent Biosciences' New Drug Application for bezuclastinib, setting a PDUFA target action date of December 30, 2026. While the stock has seen a recent 1-day gain, its 90-day return is down, yet its 1-year return shows strong momentum. Analysts have set a higher price target than its current trading price, and its Price-to-Book ratio of 10.5x indicates it is overvalued compared to the industry average, suggesting significant market optimism.
Cogent Biosciences, Inc. shares surged 7.2% in pre-market trading after the U.S. Food and Drug Administration (FDA) officially accepted its new drug application for a rare disease treatment and will initiate the review process.
Cogent Biosciences, Inc. saw its shares surge by 7.2% in pre-market trading following the U.S. FDA's acceptance of its new drug application for a rare disease treatment. This regulatory milestone signals the start of the review process and is expected to significantly boost market confidence in the company's core products. The development is crucial for the potential commercialization of the treatment.
Cogent Biosciences shares are trading higher ...
Cogent Biosciences (NASDAQ:COGT) shares are trading higher following the FDA's approval of its new drug application for bezuclastinib. The drug is intended for patients with non-advanced systemic mastocytosis. This headline-only article highlights real-time intelligence for traders.
Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib. This drug is intended for patients suffering from nonadvanced systemic mastocytosis (nonadvSM). The announcement was disseminated via Reuters and Refinitiv.
Cogent Biosciences Announces FDA Acceptance of New Drug
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat NonAdvanced Systemic Mastocytosis (NonAdvSM), setting a PDUFA target action date of December 30, 2026. The NDA is supported by positive clinical results from the SUMMIT trial, which demonstrated significant improvements and a favorable safety profile. The company also confirmed that NDA submissions for bezuclastinib in GIST and Advanced Systemic Mastocytosis are on track for April and the first half of 2026, respectively.
FDA sets Dec. 30 action date on new nonadvanced systemic mastocytosis drug
The FDA has accepted Cogent Biosciences' New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), setting a PDUFA target action date of December 30, 2026. The FDA indicated no plans for an advisory committee and identified no review issues. This acceptance follows positive results from the SUMMIT pivotal trial, showcasing significant symptomatic improvements and a favorable safety profile for long-term use.
HighVista Strategies LLC Acquires 179,219 Shares of Cogent Biosciences, Inc. $COGT
HighVista Strategies LLC has increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 63.3%, acquiring an additional 179,219 shares to reach a total of 462,405 shares, now valued at approximately $6.64 million and representing 1.6% of HighVista's portfolio. Despite significant insider selling totaling $136.6 million over the last three months, analysts maintain a "Moderate Buy" consensus rating for COGT, with an average target price of $42.82. The company, which has a market cap of $5.52 billion and a current stock price near $34, reported a quarterly EPS loss and is expected to post a full-year EPS loss of -2.42.
Cogent Biosciences, Inc. $COGT Shares Acquired by Fairmount Funds Management LLC
Fairmount Funds Management LLC significantly increased its stake in Cogent Biosciences (NASDAQ:COGT), raising its holdings by 44.6% to 9,003,418 shares, making it their second-largest position. Despite this institutional buying, the article highlights recent substantial insider selling, with a director selling 3.5 million shares and insiders overall offloading nearly 3.74 million shares. Analysts maintain a "Moderate Buy" rating with a consensus price target of $42.82, even as Cogent Biosciences remains a clinical-stage biopharma with anticipated negative EPS.
Commodore Capital LP Increases Stock Position in Cogent Biosciences, Inc. $COGT
Commodore Capital LP significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 213.7% in the third quarter, making it their fourth-largest position with shares valued at approximately $104.11 million. Despite this substantial institutional investment, analysts present a mixed view, with a consensus of "Moderate Buy" and a target price of $42.82, while insider selling by Fairmount Funds Management and John Edward Robinson amounted to approximately $136.6 million over the last quarter. Cogent Biosciences reported an EPS of ($0.55) for the most recent quarter, missing analyst estimates.
Boone Capital Management LLC Takes $13.57 Million Position in Cogent Biosciences, Inc. $COGT
Boone Capital Management LLC has acquired a new position in Cogent Biosciences, Inc. (NASDAQ:COGT), purchasing 945,042 shares valued at approximately $13.57 million, making it their 11th largest holding. Despite this significant investment and other institutional increases, Cogent Biosciences faces headwinds from recent insider selling totaling over $136 million and missed quarterly EPS estimates, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $42.82. The company, focused on small-molecule therapies for cancer, is trading at $34.00, down 3.8%.
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts
Cogent Biosciences (NASDAQ:COGT) has received a "Moderate Buy" consensus rating from analysts, with various firms setting an average one-year price target of $42.82. Despite missing quarterly EPS estimates, the company's stock trades below its 52-week high, and several analysts have recently raised their price objectives. Significant insider selling has occurred, with insiders divesting shares worth approximately $136.6 million over the last three months, though they still retain 7.29% ownership.
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?
Cogent Biosciences (NASDAQ: COGT) is highlighted as a top multibagger stock favored by billionaires, driven by strong regulatory momentum for its lead candidate, bezuclastinib. The company has submitted multiple New Drug Applications (NDAs) for severe mastocytosis and gastrointestinal stromal tumors, supported by robust clinical trial data. With substantial cash reserves from a recent offering, Cogent is well-funded to advance its diverse pipeline of precision therapies into 2028.
(COGT) Volatility Zones as Tactical Triggers
The article provides a detailed analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It presents various AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis with specific support and resistance levels. The report emphasizes an exceptional risk-reward setup targeting a 22.1% gain versus 0.3% risk.
